These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3319403)

  • 1. Computerized in vivo research from the growth of urease-producing bacteria in the presence of antibiotics combined with propionhydroxamic acid.
    Rizzo M; Nicoletti P; Bartoletti R; Luciani E
    Contrib Nephrol; 1987; 58():219-21. PubMed ID: 3319403
    [No Abstract]   [Full Text] [Related]  

  • 2. Propionhydroxamic acid in the management of struvite urinary stones.
    Puppo P; Germinale F; Bottino P; Ricciotti G; Giuliani L
    Contrib Nephrol; 1987; 58():201-6. PubMed ID: 3691127
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevention of infected urinary stones in rats by urease inhibitor: a new hydroxamic acid derivative.
    Takeuchi H; Kobashi K; Yoshida O
    Invest Urol; 1980 Sep; 18(2):102-5. PubMed ID: 6997228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physicochemical changes of urine environment on propionhydroxamic acid therapy.
    Bruno M; Marangella M; Tricerri A; Martini C; Linari F
    Contrib Nephrol; 1987; 58():207-11. PubMed ID: 3691128
    [No Abstract]   [Full Text] [Related]  

  • 5. Ureaplasma urealyticum-induced crystallization of magnesium ammonium phosphate and calcium phosphates in synthetic urine.
    Grenabo L; Brorson JE; Hedelin H; Pettersson S
    J Urol; 1984 Oct; 132(4):795-9. PubMed ID: 6381769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy for urolithiasis with hydroxamic acids. IV. Prevention of infected urinary stone formation with N-(pivaloyl)glycinohydroxamic acid.
    Satoh M; Munakata K; Kitoh K; Seto N; Kanazawa T; Takeuchi H; Yoshida O
    J Pharmacobiodyn; 1981 Jul; 4(7):469-74. PubMed ID: 7028944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S.E.M. study of urease-induced crystalluria in the presence of hydroxamic derivatives.
    Ben Amar M; L'Espérance G; Tawashi R
    Int Urol Nephrol; 1986; 18(3):227-33. PubMed ID: 3771124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro inhibition of struvite crystal growth by acetohydroxamic acid.
    Downey JA; Nickel JC; Clapham L; McLean RJ
    Br J Urol; 1992 Oct; 70(4):355-9. PubMed ID: 1450840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simple technique for studying struvite crystal growth in vitro.
    McLean RJ; Downey J; Clapham L; Nickel JC
    Urol Res; 1990; 18(1):39-43. PubMed ID: 2180168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of crystallization caused by Proteus mirabilis during the development of infectious urolithiasis by various phenolic substances.
    Torzewska A; Rozalski A
    Microbiol Res; 2014; 169(7-8):579-84. PubMed ID: 24239192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of chondroitin sulfate, heparin sulfate, and citrate on Proteus mirabilis-induced struvite crystallization in vitro.
    McLean RJ; Downey J; Clapham L; Nickel JC
    J Urol; 1990 Nov; 144(5):1267-71. PubMed ID: 2122009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose propionhydroxamic acid therapy in infection-induced stones.
    Colussi G; Surian M; De Ferrari ME; Rombolà G; Rolando P; Minetti L
    Contrib Nephrol; 1987; 58():230-2. PubMed ID: 3691134
    [No Abstract]   [Full Text] [Related]  

  • 13. Design, synthesis, molecular docking, anti-Proteus mirabilis and urease inhibition of new fluoroquinolone carboxylic acid derivatives.
    Abdullah MA; Abuo-Rahma GE; Abdelhafez EM; Hassan HA; Abd El-Baky RM
    Bioorg Chem; 2017 Feb; 70():1-11. PubMed ID: 27908539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacteriology of branched renal calculi and accompanying urinary tract infection.
    Fowler JE
    J Urol; 1984 Feb; 131(2):213-5. PubMed ID: 6422054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Urinary calculi and infection].
    Trinchieri A
    Urologia; 2014; 81(2):93-8. PubMed ID: 24874306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial dissolution of struvite calculus with oral acetohydroxamic acid.
    Rodman JS; Williams JJ; Peterson CM
    Urology; 1983 Oct; 22(4):410-2. PubMed ID: 6356559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetohydroxamate in struvite stones: in vivo study.
    Aroldi A; Graziani G; Castelnovo C; Colussi G; Surian M; Mandressi A; Mascheroni E; Pazardjiklian I; Pagano A; Ponticelli C
    Proc Eur Dial Transplant Assoc; 1983; 20():469-72. PubMed ID: 6657671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteus mirabilis biofilm protection against struvite crystal dissolution and its implications in struvite urolithiasis.
    McLean RJ; Lawrence JR; Korber DR; Caldwell DE
    J Urol; 1991 Oct; 146(4):1138-42. PubMed ID: 1895441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applicability of biosuppressin as an urease-inhibitor.
    Jávor A; Frang D; Nagy Z
    Int Urol Nephrol; 1984; 16(3):191-4. PubMed ID: 6480281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of bacterial urease.
    Griffith DP; Musher DM; Campbell JW
    Invest Urol; 1973 Nov; 11(3):234-8. PubMed ID: 4201416
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.